KR20210114946A - 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 - Google Patents

뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 Download PDF

Info

Publication number
KR20210114946A
KR20210114946A KR1020217021438A KR20217021438A KR20210114946A KR 20210114946 A KR20210114946 A KR 20210114946A KR 1020217021438 A KR1020217021438 A KR 1020217021438A KR 20217021438 A KR20217021438 A KR 20217021438A KR 20210114946 A KR20210114946 A KR 20210114946A
Authority
KR
South Korea
Prior art keywords
patient
baseline
deuterabenazine
score
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020217021438A
Other languages
English (en)
Korean (ko)
Inventor
주하-마티 사보라
마크 포레스트 고든
프랭크 슈나이더
Original Assignee
오스펙스 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오스펙스 파마슈티칼스, 인코포레이티드 filed Critical 오스펙스 파마슈티칼스, 인코포레이티드
Publication of KR20210114946A publication Critical patent/KR20210114946A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217021438A 2018-12-13 2019-12-13 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 Abandoned KR20210114946A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US62/779,232 2018-12-13
US201962801450P 2019-02-05 2019-02-05
US62/801,450 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
KR20210114946A true KR20210114946A (ko) 2021-09-24

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021438A Abandoned KR20210114946A (ko) 2018-12-13 2019-12-13 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진

Country Status (15)

Country Link
US (3) US11324732B2 (cg-RX-API-DMAC7.html)
EP (1) EP3893876A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022519007A (cg-RX-API-DMAC7.html)
KR (1) KR20210114946A (cg-RX-API-DMAC7.html)
CN (1) CN113395966A (cg-RX-API-DMAC7.html)
AU (1) AU2019395250A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011386A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123393A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001554A1 (cg-RX-API-DMAC7.html)
IL (1) IL283920A (cg-RX-API-DMAC7.html)
MX (1) MX2021007063A (cg-RX-API-DMAC7.html)
SG (1) SG11202106344SA (cg-RX-API-DMAC7.html)
TW (1) TWI784220B (cg-RX-API-DMAC7.html)
WO (1) WO2020123900A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104786B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240058028A (ko) 2022-10-24 2024-05-03 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
US20240197714A1 (en) * 2021-04-15 2024-06-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
JP2024514873A (ja) * 2021-04-15 2024-04-03 ニューロクライン バイオサイエンシーズ,インコーポレイテッド デューテトラベナジンおよびcyp2d6阻害剤の併用投与のための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
TWI772382B (zh) * 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240058028A (ko) 2022-10-24 2024-05-03 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
BR112021011386A2 (pt) 2021-08-31
EP3893876A1 (en) 2021-10-20
JP2022519007A (ja) 2022-03-18
US11324732B2 (en) 2022-05-10
CA3123393A1 (en) 2020-06-18
ZA202104786B (en) 2023-12-20
CN113395966A (zh) 2021-09-14
TWI784220B (zh) 2022-11-21
US20200188371A1 (en) 2020-06-18
MX2021007063A (es) 2021-12-10
IL283920A (en) 2021-07-29
WO2020123900A1 (en) 2020-06-18
US20220409597A1 (en) 2022-12-29
SG11202106344SA (en) 2021-07-29
TW202034917A (zh) 2020-10-01
CL2021001554A1 (es) 2022-02-11
US20240082225A1 (en) 2024-03-14
AU2019395250A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US20250302851A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
ES2879631T3 (es) Pridopidina para el tratamiento de la enfermedad de Huntington
Gaffney et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
US12390456B2 (en) Pridopidine for treating Huntington's disease
US20230321007A1 (en) Pharmacokinetics of nmda receptor antagonists
CN108135865A (zh) 使用芬氟拉明治疗Lennox-Gastaut综合征的方法
US20250352533A1 (en) Pridopidine for treating huntington's disease
EA012036B1 (ru) Мемантин для лечения расстройств поведения детского возраста
TW202102219A (zh) 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法
CN121013719A (zh) 治疗特发性震颤的方法
CN118555956A (zh) 用于治疗难治性抑郁症的赛洛西宾和辅助血清素再摄取抑制剂
JP2024517937A (ja) Nmda受容体拮抗薬の副作用の低減
WO2024216061A1 (en) Methods of treating depression and anhedonia
JP2024525424A (ja) 脳性麻痺によるジスキネジアの処置における使用のためのバルベナジン
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
EP4618973A1 (en) Methods of switching neuropsychiatric medications using ulotaront
Adler et al. Intervention Helps Workers With Depression.
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
CA2764927A1 (en) Exo-s-mecamylamine method, use, and compound for treatment
BA A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa
EA039995B1 (ru) Применение придопидина для лечения болезни хантингтона

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210708

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221202

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration